| pubmed-article:8621259 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C0027950 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C0439851 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C0162388 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C1552596 | lld:lifeskim |
| pubmed-article:8621259 | lifeskim:mentions | umls-concept:C1947931 | lld:lifeskim |
| pubmed-article:8621259 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8621259 | pubmed:dateCreated | 1996-6-18 | lld:pubmed |
| pubmed-article:8621259 | pubmed:abstractText | We have previously established that human polymorphonuclear cells (PMN) express IL-2R beta- and gamma-chains and that addition of IL-2 maintains the viability of PMN by preventing these cells from undergoing programmed cell death. The purpose of this study was to examine whether IL-2-releasing tumor cells are capable of stimulating PMN tumoricidal activity. We therefore investigated the ability of PMN to kill IL-2-transfected tumor cells using normal human PMN directed against the murine mammary adenocarcinoma TS/A engineered to release high amounts of murine IL-2 (3,600 U, B6) compared with TS/A parental cells and TS/A tumor cells transfected with the neomycin-resistance (NEO) gene only. The potency of PMN as IL-2-induced killer cells was indicated by the low number of cells required for killing (effector cell:target cell ratio 10:1) and the degree of tumor cell lysis (68+/-10%). Evidence for the role of IL-2 as a mediator of tumor cytotoxicity by PMN was substantiated by inhibition of tumor killing with anti-IL-2 and anti-IL-2R beta monoclonal antibodies (MAbs). Furthermore, in vivo depletion of mature granulocytes using MAb RB6-8C5 resulted in B6 adenocarcinoma growth, thereby confirming a direct role for IL-2-activated PMN in tumor cytolysis. Lastly, we suggest that one possible mechanism involved in IL-2-induced PMN cytotoxicity against the B6 clone occurs via the nitric oxide pathway, which could be inhibited upon addition of the arginine analog, N(G)-monomethyl-L-arginine. | lld:pubmed |
| pubmed-article:8621259 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8621259 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8621259 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8621259 | pubmed:month | May | lld:pubmed |
| pubmed-article:8621259 | pubmed:issn | 0020-7136 | lld:pubmed |
| pubmed-article:8621259 | pubmed:author | pubmed-author:DjeuJ YJY | lld:pubmed |
| pubmed-article:8621259 | pubmed:author | pubmed-author:BlanchardD... | lld:pubmed |
| pubmed-article:8621259 | pubmed:author | pubmed-author:PericleFF | lld:pubmed |
| pubmed-article:8621259 | pubmed:author | pubmed-author:KirkenR ARA | lld:pubmed |
| pubmed-article:8621259 | pubmed:author | pubmed-author:Epling-Burnet... | lld:pubmed |
| pubmed-article:8621259 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8621259 | pubmed:day | 3 | lld:pubmed |
| pubmed-article:8621259 | pubmed:volume | 66 | lld:pubmed |
| pubmed-article:8621259 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8621259 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8621259 | pubmed:pagination | 367-73 | lld:pubmed |
| pubmed-article:8621259 | pubmed:dateRevised | 2007-7-24 | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:meshHeading | pubmed-meshheading:8621259-... | lld:pubmed |
| pubmed-article:8621259 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8621259 | pubmed:articleTitle | Direct killing of interleukin-2-transfected tumor cells by human neutrophils. | lld:pubmed |
| pubmed-article:8621259 | pubmed:affiliation | Experimental Immunology Branch, NCI, NIH, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:8621259 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8621259 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8621259 | lld:pubmed |
